A cytochrome P450 BM3 mutant enzyme and its application in biocatalytic synthesis of p-hydroxybiphenyl

By mutating the amino acid of cytochrome P450 BM3 enzyme, a highly efficient cytochrome P450 BM3 mutant enzyme was developed, which solved the problems of low yield and low selectivity in the synthesis of p-hydroxybiphenyl and achieved a highly efficient and mild catalytic effect.

CN114672470BActive Publication Date: 2024-11-26HUBEI ZHONGNONG HUAWEI BIOLOGICAL ENG CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202210373930.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-04-11
Publication Date
2024-11-26
Estimated Expiration
2042-04-11

AI Technical Summary

Technical Problem

Existing technologies for the synthesis of p-hydroxybiphenyl suffer from problems such as low yield, environmental unfriendliness, and cumbersome operation, and the cytochrome P450 BM3 enzyme has low selectivity for non-natural substrates.

Method used

By mutating amino acids at positions 87 and/or 267 of the cytochrome P450 BM3 enzyme, cytochrome P450 BM3 mutant enzymes, specifically E267V or F87G mutants, were developed and expressed in Escherichia coli via nucleic acid molecules and expression vectors. The enzyme was then used to catalyze the synthesis of p-hydroxybiphenyl from biphenyl.

Benefits of technology

The catalytic efficiency was improved, with the catalytic activity of the mutant enzyme increasing by 1.5 times compared to the wild type. The reaction conditions were mild, requiring no high temperature or high pressure, and the selectivity was improved.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114672470B_ABST
    Figure CN114672470B_ABST
Patent Text Reader

Abstract

The present invention provides a cytochrome P450BM3 mutant enzyme and its application in biocatalytic synthesis of p-hydroxybiphenyl. The cytochrome P450BM3 mutant enzyme is an amino acid mutation in the 87th and 267th positions of the amino acid sequence of the wild-type cytochrome P450BM3 monooxygenase, specifically including: A. The cytochrome P450BM3 mutant enzyme is a point mutation at a single site, and the point mutation includes: E267V or F87G; B. Or the cytochrome P450BM3 mutant enzyme is a mutation at two sites, which are E267V and F87G. The hydroxylation activity of the cytochrome P450 monooxygenase mutant P450BM3 provided by the present invention for biphenyl is nearly 1.5 times higher than that of the wild-type CYP, and has a relatively stable catalytic effect. And the reaction conditions are mild, without a high temperature and high pressure environment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of bioengineering, and in particular to a cytochrome P450 BM3 mutant enzyme and application thereof in biocatalytic synthesis of p-hydroxybiphenyl. Background Art

[0002] Para-hydroxybiphenyl is a white needle-like or flaky solid with a molecular formula of C 12 H 10 O, molecular weight is 170, CAS number is 92-69-3, melting point is 164.5℃, boiling point is 306.5℃, and it is almost insoluble in water. It can be used as a dye; an intermediate of resin and rubber. The red light sensitizing and green light sensitizing dyes synthesized with it are one of the main raw materials for color films. It can also be used as an analytical reagent, such as colorimetric determination of acetaldehyde and lactic acid, and quantitative determination of muramic acid. Inhibitor of deoxyribonuclease I. Intermediate of dye, resin and rubber, bactericide, solubilizer for water-soluble paint. Its synthesis mainly uses the by-product distillation residue of phenol produced by sulfonation as raw material, and intercepts the phenylphenol fraction by vacuum distillation, and then uses the difference in solubility of o-phenylphenol and p-phenylphenol in trichloroethylene to achieve isomer separation. It can also be obtained by hydrolyzing p-chlorobiphenyl at high temperature. This method has problems such as low yield, environmental protection, and cumbersome operation.

[0003] Cytochrome P450 monooxygenase (P450) can catalyze the oxidation of various organic compounds with complex skeletons with high efficiency and selectivity, and is known as the universal catalyst of nature. In recent years, there has been an increasing number of studies on the use of P450 monooxygenase to catalyze CH bond activation. P450 BM3 (CYP102A1) is a fatty acid hydroxylase derived from Bacillus megaterium. Its uniqueness lies in that P450 BM3 is a fusion enzyme of a natural heme iron-dependent monooxygenase and an NADPH-dependent flavin reductase that can transfer electrons. It has a self-sufficient electron transfer system and can start the reaction by adding only NADPH. This advantage of P450 BM3 monooxygenase has made it a research hotspot in recent years, especially for its low selectivity for non-natural substrates. It has been modified through directed evolution through protein engineering to control its selectivity and even create new reaction types that the original P450 cannot catalyze.

[0004] Therefore, it is necessary to develop a cytochrome P450 mutant with higher catalytic efficiency for biocatalytic synthesis of p-hydroxybiphenyl. Summary of the invention

[0005] The purpose of the present invention is to provide a catalytic product and its application in the biocatalytic synthesis of p-hydroxybiphenyl, and to screen out a cytochrome P450 BM3 mutant enzyme, which has a higher catalytic efficiency than the wild type.

[0006] In a first aspect of the present invention, a cytochrome P450 BM3 mutant enzyme is provided, wherein the cytochrome P450 BM3 mutant enzyme is subjected to an amino acid mutation at position 87 and / or position 267 of the amino acid sequence of a wild-type cytochrome P450 BM3 monooxygenase, comprising:

[0007] Further, the cytochrome P450 BM3 mutant enzyme is a point mutation at a single site, and the point mutation includes: E267V or F87G;

[0008] Alternatively, the cytochrome P450 BM3 mutant enzyme has mutations at two sites, namely, E267V and F87G.

[0009] Furthermore, the nucleotide sequence encoding the cytochrome P450 BM3 mutant enzyme is shown in SEQ ID NO: 2 or SEQ ID NO: 3.

[0010] In a second aspect of the present invention, a nucleic acid molecule encoding the cytochrome P450 BM3 mutant enzyme is provided.

[0011] In the third aspect of the present invention, a cytochrome P450 BM3 mutant enzyme expression vector is provided, wherein the expression vector comprises the nucleic acid molecule.

[0012] Furthermore, the expression vector comprises one of a prokaryotic expression vector and a viral vector.

[0013] In the fourth aspect of the present invention, a recombinant bacterium or an engineered cell line comprising the expression vector is provided.

[0014] In the fifth aspect of the present invention, there is provided a use of the cytochrome P450 BM3 mutant enzyme, the nucleic acid molecule, the expression vector, the recombinant bacteria or the engineered cell line in catalytic synthesis of p-hydroxybiphenyl.

[0015] In the sixth aspect of the present invention, a method for catalyzing biphenylin to synthesize p-hydroxybiphenyl is provided, the method comprising: using biphenyl as a substrate and using the cytochrome P450 BM3 mutant enzyme to catalyze the synthesis of the product p-hydroxybiphenyl.

[0016] Furthermore, the method specifically comprises: adding the cytochrome P450 BM3 mutant enzyme to a buffered reaction solution, then adding substrate biphenyl and NADPH to mix and perform a biocatalytic reaction, and obtaining p-hydroxybiphenyl after separation.

[0017] Add a certain concentration of enzyme and substrate to the buffer solution, and then add coenzyme NADPH to start the reaction and realize the catalytic oxidation of the substrate. Vibration during the reaction can accelerate the reaction. The final concentration of coenzyme NADPH is preferably 200-300 μM. Increasing the amount of enzyme and coenzyme will speed up the reaction and facilitate synthesis. The amount of enzyme is adjusted according to the substrate concentration.

[0018] Furthermore, the temperature of the catalytic reaction is 36-38° C. After the reaction is completed, anhydrous ethanol is added to quench the reaction, and the mixture is centrifuged at 12000 rpm for 2 min to detect the generation of the product by high performance liquid chromatography.

[0019] As a preferred embodiment, when biphenyl is used as a substrate, ethanol is used for dissolution. In a specific embodiment of the present invention, the ethanol content in the reaction system should not exceed 2% of the total system. As a specific embodiment, when ethanol is used as a solvent for dissolution, the final concentration of biphenyl is preferably 35-45 mM;

[0020] The buffered reaction solution is preferably a potassium phosphate buffer with a concentration of 45 to 55 mM and a pH of 7.8 to 8.2.

[0021] One or more technical solutions in the embodiments of the present invention have at least the following technical effects or advantages:

[0022] The present invention provides a catalytic product and its application in biocatalytic synthesis of p-hydroxybiphenyl. The cytochrome P450 monooxygenase mutant P450 BM3 provided by the present invention has a hydroxylation activity of p-hydroxybiphenyl that is nearly 1.5 times higher than that of the wild-type CYP, and has a relatively stable catalytic effect. The reaction conditions are mild, and there is no high temperature and high pressure environment. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the following briefly introduces the drawings required for use in the description of the embodiments. Obviously, the drawings described below are some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work.

[0024] Figure 1 This is the plasmid map of pRSFduet;

[0025] Figure 2 The SDS-PAGE results of P450 BM3 (E267V / F87G) protein;

[0026] Figure 3 This is the HPLC test result of enzyme-catalyzed biphenyl to form p-hydroxybiphenyl;

[0027] Figure 4is the agarose gel electrophoresis result of pRSFduet-BM3;

[0028] Figure 5 is the standard curve graph; DETAILED DESCRIPTION

[0029] The present invention will be described in detail below in conjunction with specific implementations and examples, and the advantages and various effects of the present invention will be more clearly presented. It should be understood by those skilled in the art that these specific implementations and examples are used to illustrate the present invention, rather than to limit the present invention.

[0030] Throughout the specification, unless otherwise specifically stated, the terms used herein should be understood as meanings commonly used in the art. Therefore, unless otherwise defined, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art to which the present invention belongs. In the event of a conflict, the present specification takes precedence.

[0031] Unless otherwise specified, various raw materials, reagents, instruments and equipment used in the present invention can be purchased from the market or obtained by existing methods.

[0032] A catalytic product of the present application and its application in the biocatalytic synthesis of p-hydroxybiphenyl will be described in detail below in combination with examples and experimental data.

[0033] Example 1. Construction of expression vector for cytochrome P450 BM3 mutant enzyme and engineering bacteria

[0034] 1. Acquisition of P450 BM3 gene

[0035] The Bacillus megaterium purchased from the strain collection center in the laboratory was subcultured and the genome was extracted using a genome extraction kit, and the extraction steps were carried out according to the product instructions.

[0036] According to the P450 BM3 gene sequence published on the NCBI website (shown in SEQ ID NO: 1), Snapgen software was used to assist in designing PCR amplification primers. The primers were synthesized by Shanghai Bioengineering, see Table 1.

[0037] Table 1 - P450 BM3 PCR Primers

[0038]

[0039]

[0040] The extracted genome was used as a template to amplify the target gene using the 2×Taq Plus PCR MasterMix kit produced by Tiangen Biochemical Technology Co., Ltd. The PCR reaction conditions were as follows: 25 μL of 2×Taq Plus PCR MasterMix, 2.5 μL of 10 μM upstream primers and downstream primers (see Table 1), 1 μL of plasmid template, and sterilized distilled water to 50 μL were added to a total volume of 50 μL of PCR reaction system. PCR reaction procedure: (1) 94°C pre-denaturation for 3 min, (2) 94°C denaturation for 30 sec, (3) 55°C annealing for 30 sec, (4) 72°C extension for 3.5 min, steps (2) to (4) were performed for a total of 30 cycles. The PCR product was stored at 4°C.

[0041] After the PCR was completed, samples were taken for agarose gel electrophoresis to test the amplification results, and the gel concentration was 1%. The reaction system was treated with the DP214 DNA purification kit produced by Tiangen Biochemical Technology Co., Ltd. (the process was carried out according to the instructions) to obtain the PCR amplification product. It was stored at -20°C.

[0042] 2. Plasmid construction

[0043] Obtain the target gene and pRSFduet expression vector (plasmid map as shown in Figure 1 After that, add double distilled water, endonuclease buffer, enzyme substrate, and restriction endonuclease (BamHI and EcoRI purchased from NEB, use the specifications and methods according to the instructions) to the PCR tube for double enzyme digestion reaction, and add the order from most to least. The target gene and pRSFduet are placed at 37°C for double enzyme digestion. The reaction system is as follows:

[0044] Table 2-P450 BM3 gene fragment double enzyme digestion system:

[0045]

[0046] Table 3-pRSFduet double enzyme digestion system:

[0047]

[0048] After double digestion reaction with BamHI and EcoRI restriction endonucleases at 37°C for 3 h, Loading Buffer was added to terminate the reaction, and the double digestion product was purified and recovered according to the instructions of the DP214 DNA purification kit produced by Tiangen Biochemical Technology Co., Ltd.

[0049] After being cut by the same restriction endonuclease, the double-digestion products have the same sticky ends and can be connected to a complete plasmid by DNA ligase. The P450 BM3 gene and pRSFduet double-digestion products with the same sticky ends are placed in the same PCR tube. The ligation reaction uses a 10μL system, and the target gene and plasmid digestion products are added in a ratio of 3:1, mixed with 1μL T4 DNA ligase (purchased from NEB), and connected overnight at 16°C. The successfully connected plasmid is named pRSFduet-BM3. The results of agarose gel electrophoresis are shown in Figure 4 .Depend on Figure 4 It can be seen that the size of the constructed pRSFduet-BM3 is consistent with expectations.

[0050] 3. Conversion

[0051] The ligation product was transformed into E. coli DH5α competent cells. The transformation steps are as follows:

[0052] 1) First adjust the temperature of the constant temperature water bath to 42°C.

[0053] 2) Take a tube (100 μl) of competent bacteria out of the -80°C ultra-low temperature freezer, immediately melt it with your fingers, then insert it into ice and place it in an ice bath for 10 minutes.

[0054] 3) Add 10 μl of the ligation product pRSFduet-BM3, shake gently and place on ice for 20 minutes.

[0055] 4) After gently shaking, place it in a 42°C water bath for 90 seconds of heat shock, then quickly return it to ice and let it stand for 5 minutes.

[0056] 5) Add 900 μL of LB medium without antibiotics to each of the above tubes and mix gently, then fix them on the spring frame of the shaker and shake them at 37 degrees Celsius for 50 minutes.

[0057] 6) Add 300 μl of the above transformation mixture taken out from the clean bench to each solid LB plate culture dish containing the appropriate antibiotic, and evenly apply it using a glass coating rod that has been burned with an alcohol lamp and cooled.

[0058] 7) Place the marked culture dish in a 37°C constant temperature incubator for 30-60 minutes. After the surface liquid has penetrated into the culture medium, turn it upside down and place it in a 37°C constant temperature incubator overnight.

[0059] The single colony grown was used for recombinant plasmid identification: the single colony grown on the above LB solid medium was picked, inoculated into 5mL LB medium containing kanamycin, and cultured overnight at 37℃ and 200r·min-1. A part of the bacterial solution was taken and stored in a glycerol tube. The recombinant plasmid was extracted according to the instructions of the plasmid extraction kit. The extracted recombinant plasmid was double-digested with BamHI and EcoRI, which was the same as the double-digestion system of pRSFduet. The product after double-digestion was analyzed by 1% agarose gel electrophoresis for the target gene fragment and the vector fragment. The recombinant plasmid identified as positive by double-digestion was then sent to Shanghai Biotech for sequence determination. If the determination was successful, the next experiment was carried out.

[0060] 4. Enzyme mutation

[0061] In order to improve the synthesis efficiency of p-hydroxybiphenyl, firstly, E267V&F87G mutations were introduced into the plasmid pRSFduet-BM3 by PCR (wherein, the sequence of the F87G point mutation is shown in SEQ ID NO.2, and the sequence of the E267V point mutation is shown in SEQ ID NO.3), primers were designed (primer sequences are shown in Table 4), and QuikChange mutagenesis was performed using the Q5 PCR MasterMix kit produced by NEB. The PCR reaction conditions were as follows: 25 μL of 2×Master Mix, 2.5 μL of 10 μM upper primers and lower primers (as shown in Table 4), 1 μL of plasmid template, and sterilized distilled water was added to a PCR reaction system with a total volume of 50 μL. PCR reaction procedure: (1) pre-denaturation at 98°C for 30 seconds, (2) denaturation at 98°C for 10 seconds, (3) annealing at 55°C for 30 seconds, (4) extension at 72°C for 3.5 minutes, steps (2) to (4) were repeated 30 times in total. The PCR product was stored at 4°C.

[0062] Table 4 - Primer sequences of mutation sites

[0063]

[0064] After the PCR product was verified by agarose gel electrophoresis analysis, restriction endonuclease DpnI was added and digested at 37°C for 2h. The digestion product was transformed into E. coli BL21 (DE3) competent cells and spread on a plate containing kanamycin, and placed in a 37°C incubator for static culture for about 12h. Single clones were selected for sequencing, and the corresponding mutant bacteria, i.e., cytochrome P450 BM3 mutant F87G and cytochrome P450 BM3 mutant E267V, were obtained if the sequencing was correct.

[0065] Example 2 Protein expression and purification

[0066] The present embodiment provides a method of expressing and purifying the mutant bacteria (cytochrome P450 BM3 mutant F87G and cytochrome P450 BM3 mutant E267V) obtained in Example 1 in Escherichia coli to obtain cytochrome P450 BM3 mutant enzymes (mutant F87G and mutant E267V), which specifically includes the following steps:

[0067] 1. Culture media and buffers used in protein expression and purification

[0068] LB medium: 10 g / L tryptone, 10 g / L sodium chloride, 5 g / L yeast extract powder;

[0069] Wash buffer: 10 mM imidazole, 50 mM K2HPO4-KH2PO4, 300 mM NaCl, 10% glycerol, pH 8.0;

[0070] Elution buffer: 200 mM imidazole, 50 mM K2HPO4-KH2PO4, 300 mM NaCl, 10% glycerol, pH 8.0;

[0071] Storage buffer: 50 mM K2HPO4-KH2PO4, 300 mM NaCl, 10% glycerol, pH 8.0.

[0072] 2. Protein Expression

[0073] The glycerol bacteria containing the recombinant plasmid were inoculated into 6 mL of LB medium (containing 50 mg / L kanamycin sulfate) and cultured overnight at 37°C and 220 rpm for 14 h;

[0074] Transfer overnight culture seeds to 500 mL LB medium at a ratio of 1:100 and culture at 37°C, 150 rpm until OD600 = 0.5;

[0075] The expression of genes on the pRSFduet vector was induced with 0.7 mM IPTG, and cultured overnight at 18°C ​​and 150 rpm for 24 h after induction;

[0076] The cells were collected by centrifugation at 4000 g for 5 min at 4°C, resuspended in 30 mL of storage buffer, and then disrupted with an ultrasonic disruptor (operating for 3 s, interval of 7 s, time for 10 min, ultrasonic power of about 200 W);

[0077] The disrupted cell suspension was centrifuged at 12,000 rpm and 4°C for 30 min. The resulting supernatant was the crude protein enzyme solution, which could be used for enzyme activity testing and subsequent protein purification experiments.

[0078] 3. Protein purification

[0079] The target protein is fused with a His tag at the C-terminus, so the protein can be purified by affinity chromatography.

[0080] The present invention adopts Ni-NTA purification medium of Shanghai Biotech to purify the protein.

[0081] (1) Add 6 mL of Ni-NTA purification medium into a 50 mL empty chromatography column, allow the medium to settle freely, and drain the storage solution;

[0082] (2) adding 4 column volumes of wash buffer to equilibrate the chromatography medium;

[0083] (3) Load the clarified sample containing the His-tagged protein onto the column at a flow rate of 0.5 mL / min;

[0084] (4) washing the column with wash buffer at a flow rate of 1 mL / min and a flow rate of 10 column volumes to remove contaminants;

[0085] (5) eluting with 5 column volumes of elution buffer at a flow rate of 0.5-1 mL / min and collecting the eluate;

[0086] (6) Collect the eluate and use a Millipore ultrafiltration tube (15mL 30kDa) to desalt and concentrate the purified protein. Place 10mL of the eluate in an ultrafiltration tube with the collection tube at the bottom. Centrifuge at 4°C, 3500rpm for 20min. Retain about 1.5mL of protein in the upper ultrafiltration tube. The buffer containing imidazole is at the bottom. Pour out the solution in the collection tube, and then make up the volume to 10ml with the storage buffer. Repeat the above steps for 3 times and use a pipette to aspirate the protein in the ultrafiltration tube. Determine the protein concentration by the Coomassie Brilliant Blue method and store it at -80°C for future use. The method for measuring protein concentration by Coomassie Brilliant Blue was determined by reference to the literature (Li Juan, Zhang Yaoting, Zeng Wei, et al. Determination of total protein content by Coomassie Brilliant Blue Method [J]. Chinese Journal of Biological Products (02): 118-120.). The SDS-PAGE results of P450 BM3 (E267V / F87G) protein are shown in the figure. Figure 2 The results show that the E267V and F87G proteins were successfully purified.

[0087] Example 3: Synthesis of p-Hydroxybiphenyl from biphenyl using biocatalysis

[0088] In this example, biphenyl is used as a substrate to synthesize p-hydroxybiphenyl through enzyme catalysis. The total volume of the reaction system in this example is 1 ml. Reaction systems of other specifications can be adjusted accordingly with reference to this reaction system.

[0089] 1. Substrate preparation

[0090] The substrate biphenyl was dissolved in ethanol to obtain a stock solution with a final concentration of 40 mM;

[0091] 2. Preparation of reaction buffer

[0092] The reaction buffer was 50 mM K2HPO4-KH2PO4 buffer, pH 8.0.

[0093] 3. Catalytic reaction

[0094] In the buffer system, add the enzyme (mutant F87G or mutant E267V) at a final concentration of 0.3 mg / mL, then add 10 μL substrate biphenyl (dissolved in ethanol) to a final concentration of 400 μM, add NADPH at a final concentration of 250 μM, and the total volume is 1 ml. 37°C, 200 rpm for 10 min, immediately take out, add 1 ml of ethanol to quench the reaction, centrifuge at 12000 rpm for 2 min, filter with a 0.22 μm membrane (produced by Jinteng), and analyze and detect with HPLC.

[0095] 4. HPLC separation and detection

[0096] Agilent C18, 15cm column was used, the mobile phase was methanol: water = 88:12, column temperature was 30℃, flow rate was 1mL / min, substrate and product were detected at 254nm of UV detector. The peak time of product p-hydroxybiphenyl was about 3.5min, and the peak time of substrate biphenyl was about 6.5min.

[0097] 5. Drawing of standard curve

[0098] Prepare 400 μM stock solution of p-hydroxybiphenyl with ethanol, prepare 6 10 ml volumetric flasks, dilute to final concentrations of 5, 10, 20, 40, 80, 160 μM samples, filter with 0.22 μm membrane and perform liquid phase detection. Repeat 3 times for each group, draw a standard curve with absorbance as the horizontal axis and concentration as the vertical axis. The standard curve is as follows: Figure 5 shown.

[0099] Definition of enzyme specific activity: The amount of p-hydroxybiphenyl generated by a certain amount of mutant enzyme within 1 min when the biphenyl concentration is 400 μM, unit is μM indigo (mg protein min)

[0100] Depend on Figure 5 It can be seen that the specific enzyme activity of the wild-type P450 BM3 is 7.01μM indigo, the specific enzyme activity of the mutant E267V is 10.36μMindigo, which is 47% higher than that of the wild-type; the specific enzyme activity of the mutant F87G is 9.31μM indigo, which is 32% higher than that of the wild-type.

[0101] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.

[0102] Finally, it should be noted that the terms "comprises," "includes," or any other variations thereof are intended to cover non-exclusive inclusion, such that a process, method, article, or apparatus that includes a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements that are inherent to such process, method, article, or apparatus.

[0103] Although the preferred embodiments of the present invention have been described, those skilled in the art may make other changes and modifications to these embodiments once they have learned the basic creative concept. Therefore, the appended claims are intended to be interpreted as including the preferred embodiments and all changes and modifications that fall within the scope of the present invention.

[0104] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations. Sequence Listing <110> Hubei Zhongnong Huawei Bioengineering Co., Ltd. <120> A cytochrome P450 BM3 mutant enzyme and its application in biocatalytic synthesis of p-hydroxybiphenyl <160> 9 <170> SIPOSequenceListing 1.0 <210> 1 <211> 3147 <212> DNA <213> Artificial Sequence <400> 1 gcaattaaag aaatgcctca gccaaaaacg tttggagagc ttaaaaattt accgttatta 60 aacacagata aaccggttca agctttgatg aaaattgcgg atgaattagg agaaatcttt 120 aaattcgagg cgcctggtcg tgtaacgc tacttatcaa gtcagcgtct attaaagaa 180 gcatgcgatg aatcacgctt tgataaaaac ttaagtcaag cgcttaaatt tgtacgtgat 240 tttgcaggag acgggttatt tacaagctgg acgcatgaaa aaaattggaa aaaagcgcat 300 aatatcttac ttccaagctt cagtcagcag gcaatgaaag gctatcatgc gatgatggtc 360 gatatcgccg tgcagcttgt tcaaaagtgg gagcgtctaa atgcagatga gcatattgaa 420 gtaccggaag acatgacacg tttaacgctt gatacaattg gtctttgcgg ctttaactat 480 cgctttaaca gcttttaccg agatcagcct catccattta ttacaagtat ggtccgtgca 540 ctggatgaag caatgaacaa gctgcagcga gcaaatccag acgacccagc ttatgatgaa 600 aacaagcgcc agtttcaaga agatatcaag gtgatgaacg acctagtaga taaaattatt 660 gcagatcgca aagcaagcgg tgaacaaagc gatgattat taacgcatat gctaaacgga 720 aaagatccag aaacgggtga gccgcttgat gacgagaaca ttcgctatca aattattaca 780 ttcttaattg cgggacacga aacaacaagt ggtcttttat catttgcgct gtatttctta 840 gtgaaaaatc cacatgtatt acaaaaagca gcaagaagaag cagcacgagt tctagtagat 900 cctgttccaa gctacaaaca agtcaaacag cttaaatatg tcggcatggt cttaaacgaa 960 gcgctgcgct tatggccaac tgctcctgcg ttttccctat atgcaaaaga agatacggtg 1020 cttggaggag aatatccttt agaaaaaggc gacgaactaa tggttctgat tcctcagctt 1080 caccgtgata aaacaatttg gggagacgat gtggaagagt tccgtccaga gcgttttgaa 1140 aatccaagtg cgattccgca gcatgcgttt aaaccgtttg gaaacggtca gcgtgcgtgt 1200 atcggtcagc agttcgctct tcatgaagca acgctggtac ttggtatgat gctaaaacac 1260 tttgactttg aagatcatac aaactacgag ctggatatta aagaaacttt aacgttaaaa 1320 cctgaaggct ttgtggtaaa agcaaaatcg aaaaaaaattc cgcttggcgg tattccttca 1380 cctagcactg aacagtctgc taaaaaagta cgcaaaaagg cagaaaacgc tcataatacg 1440 ccgctgcttg tgctatacgg ttcaaatatg ggaacagctg aaggaacggc gcgtgattta 1500 gcagatattg caatgagcaa aggatttgca ccgcaggtcg caacgcttga ttcacacgcc 1560 ggaaatcttc cgcgcgaagg agctgtatta attgtaacgg cgtcttataa cggtcatccg 1620 cctgataacg caaagcaatt tgtcgactgg ttagaccaag cgtctgctga tgaagtaaaa 1680 ggcgttcgct actccgtatt tggatgcggc gataaaaact gggctactac gtatcaaaaa 1740 gtgcctgctt ttatcgatga aacgcttgcc gctaaagggg cagaaaacat cgctgaccgc 1800 ggtgaagcag atgcaagcga cgactttgaa ggcacatatg aagaatggcg tgaacatatg 1860 tggagtgacg tagcagccta ctttaacctc gacattgaaa acagtgaaga taataaatct 1920 actctttcac ttcaatttgt cgacagcgcc gcggatatgc cgcttgcgaa aatgcacggt 1980 gcgttttcaa cgaacgtcgt agcaagcaaa gaacttcaac agccaggcag tgcacgaagc 2040 acgcgacatc ttgaaattga acttccaaaa gaagcttctt atcaagaagg agatcattta 2100 ggtgttattc ctcgcaacta tgaaggaata gtaaaccgtg taacagcaag gttcggccta 2160 gatgcatcac agcaaatccg tctggaagca gaagaagaaa aattagctca tttgccactc 2220 gctaaaacag tatccgtaga agagcttctg caatacgtgg agcttcaaga tcctgttacg 2280 cgcacgcagc ttcgcgcaat ggctgctaaa acggtctgcc cgccgcataa agtagctt gaagccttgc ttgaaaagca agcctacaaa gaacagtgc tggcaaaacg tttaacaatg cttgaactgc ttgaaaata cccggcgtgt gaatgaat tcagcgaatt tatcgccctt ctgccaagca tacgcccgcg ctattactcg atttcttcat cacctcgtgt cgatgaaaaa caagcaagca tcacggtcag cgttgtctca ggagaagcgt ggagcggata tggagaatat aaaggaattg cgtcgaacta tcttgccgag ctgcaagaag gagatacgat tacgtgcttt atttccacac cgcagtcaga atttacgctg ccaaaagacc ctgaaacgcc gcttatcatg gtcggaccgg gaacaggcgt cgcgccgttt agaggctttg tgcaggcgcg caaacagcta 2820. aaagaacaag gacagtcact tggagaagca catttatact tcggctgccg ttcacctcat gaagactatc tgtatcaaga agagcttgaa aacgcccaaa gcgaaggcat cattacgctt cataccgctt tttctcgcat gccaaatcag ccgaaaacat acgttcagca cgtaatggaa caagacggca agaaattgat tgaacttctt gatcaaggag cgcacttcta tatttgcgga gacggaagcc aaatggcacc tgccgttgaa gcaacgctta tgaaaagcta tgctgacgtt 3060 caccaagtga gtgaagcaga cgctcgctta tggctgcagc agctagaaga aaaaggccga 3120 tacgcaaaag acgtgtgggc tgggtaa 3147 <210> 2 <211> 3147 <212> DNA <213> Artificial Sequence <400> 2 gcaattaaag aaatgcctca gccaaaaacg tttggagagc ttaaaaattt accgttatta 60 aacacagata aaccggttca agctttgatg aaaattgcgg atgaattagg agaaatcttt 120 aaattcgagg cgcctggtcg tgtaacgcgc tacttatcaa gtcagcgtct aattaaagaa 180 gcatgcgatg aatcacgctt tgataaaaac ttaagtcaag cgcttaaatt tgtacgtgat 240 tttgcaggag acgggttagg tacaagctgg acgcatgaaa aaaattggaa aaaagcgcat 300 aatatcttac ttccaagctt cagtcagcag gcaatgaaag gctatcatgc gatgatggtc 360 gatatcgccg tgcagcttgt tcaaaagtgg gagcgtctaa atgcagatga gcatattgaa 420 gtaccggaag acatgacacg tttaacgctt gatacaattg gtctttgcgg ctttaactat 480 540. cgctttaaca gcttttaccg agatcagcct catccattta ttacaagtat ggtccgtgca ctggatgaag caatgaacaa gctgcagcga gcaaatccag acgacccagc ttatgatgaa aacaagcgcc agtttcaaga agatatcaag gtgatgaacg acctagtaga taaaattatt gcagatcgca aagcaagcgg tgaacaaagc gatgatttat taacgcatat gctaaacgga aaagatccag aaacgggtga gccgcttgat gacgagaaca ttcgctatca aattattaca ttcttaattg cgggacacga aacaacaagt ggtcttttt catttgcgct gtattctta gtgaaaaatc cacatgtatt acaaaaagca gcagaagaag cagcacgagt tctagtagat cctgttccaa gctacaaaca agtcaaacag cttaaatatg tcggcatggt cttaaacgaa gcgctgcgct tatggccaac tgctcctgcg ttttccctat atgcaaaaga agatacggtg cttggaggag aatatccttt agaaaaaggc gacgaactaa tggttctgat tcctcagctt caccgtgata aaacaatttg gggagacgat gtggaagagt tccgtccaga gcgttttgaa aatccaagtg cgattccgca gcatgcgttt aaaccgtttg gaaacggtca gcgtgcgtgt atcggtcagc agttcgctct tcatgaagca acgctggtac ttggtatgat gctaaaacac 1260 tttgactttg aagatcatac aaactacgag ctggatatta aagaaacttt aacgttaaaa 1320 cctgaaggct ttgtggtaaa agcaaaatcg aaaaaaaattc cgcttggcgg tattccttca 1380 cctagcactg aacagtctgc taaaaaagta cgcaaaaagg cagaaaacgc tcataatacg 1440 ccgctgcttg tgctatacgg ttcaaatatg ggaacagctg aaggaacggc gcgtgattta 1500 gcagatattg caatgagcaa aggatttgca ccgcaggtcg caacgcttga ttcacacgcc 1560 ggaaatcttc cgcgcgaagg agctgtatta attgtaacgg cgtcttataa cggtcatccg 1620 cctgataacg caaagcaatt tgtcgactgg ttagaccaag cgtctgctga tgaagtaaaa 1680 ggcgttcgct actccgtatt tggatgcggc gataaaaact gggctactac gtatcaaaaa 1740 gtgcctgctt ttatcgatga aacgcttgcc gctaaagggg cagaaaacat cgctgaccgc 1800 ggtgaagcag atgcaagcga cgactttgaa ggcacatatg aagaatggcg tgaacatatg 1860 tggagtgacg tagcagccta ctttaacctc gacattgaaa acagtgaaga taataaatct 1920 actcttcac ttcaatttgt cgacagcgcc gcggatatgc cgcttgcgaa atgcacggt 1980 gcgttttcaa cgaacgtcgt agcaagcaa gaacttcaac agccaggcag tgcacgaagc 2040 acgcgacatc ttgaattga acttccaaaa gaagctctt atcaagaagg agatcattta 2100 gtgttattc ctcgcaacta tgaaggaata gtaaccgtg taacagcaag gttcggccta 2160 gatgcatcac agcaatccg tctggaagca gagagaaa attackca tttgccactc 2220 gctaaaacag tatccgtaga agagctctg caatacgtgg agctcaaga tcctgttacg 2280 cgcacgcagc ttcgcgcaat ggctgctaaa acggtctgcc cgccgcataa agtagagctt 2340 gaagccttgc tgaaaagca agcctacaa gaacaagtgc tggcaaacg ttacaatg 2400 cttgaactgc ttgaaaata cccggcgtgt gaatgaaat tcagcgaatt tatcgccctt 2460 ctgccaagca tacgcccgcg ctattactcg atttctcat cacctcgtgt cgatgaaaaa 2520 caagcaagca tcacggtcag cgttgtctca ggagaagcgt ggagcggata tggaatat 2580 aaaggaattg cgtcgaacta tcttgccgag ctgcaagag gagatacgat tacgtgcttt 2640 atttccacac cgcagtcaga atttacgctg ccaaaagacc ctgaaacgcc gcttatcatg 2700 gtcggaccgg gaacaggcgt cgcgccgttt agaggctttg tgcaggcgcg caaacagcta 2760 aaagaacaag gacagtcact tggagaagca catttatact tcggctgccg ttcacctcat 2820 gaagactatc tgtatcaaga agagcttgaa aacgcccaaa gcgaaggcat cattacgctt 2880 cataccgctt tttctcgcat gccaaatcag ccgaaaacat acgttcagca cgtaatggaa 2940 caagacggca agaaattgat tgaacttctt gatcaaggag cgcacttcta tatttgcgga 3000 gacggaagcc aaatggcacc tgccgttgaa gcaacgctta tgaaaagcta tgctgacgtt 3060 caccaagtga gtgaagcaga cgctcgctta tggctgcagc agctagaaga aaaaggccga 3120 tacgcaaaag acgtgtgggc tgggtaa 3147 <210> 3 <211> 3147 <212> DNA <213> Artificial Sequence <400> 3 gcaattaaag aaatgcctca gccaaaaacg tttggagagc ttaaaaattt accgttatta 60 aacacagata aaccggttca agctttgatg aaaattgcgg atgaattagg agaaatcttt 120 aaattcgagg cgcctggtcg tgtaacgc tacttatcaa gtcagcgtct attaaagaa 180 gcatgcgatg aatcacgctt tgataaaaac ttaagtcaag cgcttaaatt tgtacgtgat 240 tttgcaggag acgggttatt tacaagctgg acgcatgaaa aaaattggaa aaaagcgcat 300 aatatcttac ttccaagctt cagtcagcag gcaatgaaag gctatcatgc gatgatggtc 360 gatatcgccg tgcagcttgt tcaaaagtgg gagcgtctaa atgcagatga gcatattgaa 420 gtaccggaag acatgacacg tttaacgctt gatacaattg gtctttgcgg ctttaactat 480 cgctttaaca gcttttaccg agatcagcct catccattta ttacaagtat ggtccgtgca 540 ctggatgaag caatgaacaa gctgcagcga gcaaatccag acgacccagc ttatgatgaa 600 aacaagcgcc agtttcaaga agatatcaag gtgatgaacg acctagtaga taaaattatt 660 gcagatcgca aagcaagcgg tgaacaaagc gatgattat taacgcatat gctaaacgga 720 aaagatccag aaacgggtga gccgcttgat gacgagaaca ttcgctatca aattattaca 780 ttcttaattg cgggacacgt aacaacaagt ggtcttttat catttgcgct gtatttctta 840 gtgaaaaatc cacatgtatt acaaaaagca gcaagaagaag cagcacgagt tctagtagat 900 cctgttccaa gctacaaaca agtcaaacag cttaaatatg tcggcatggt cttaaacgaa 960 gcgctgcgct tatggccaac tgctcctgcg ttttccctat atgcaaaaga agatacggtg 1020 cttggaggag aatatccttt agaaaaaggc gacgaactaa tggttctgat tcctcagctt 1080 caccgtgata aaacaatttg gggagacgat gtggaagagt tccgtccaga gcgttttgaa 1140 aatccaagtg cgattccgca gcatgcgttt aaaccgtttg gaaacggtca gcgtgcgtgt 1200 atcggtcagc agttcgctct tcatgaagca acgctggtac ttggtatgat gctaaaacac 1260 tttgactttg aagatcatac aaactacgag ctggatatta aagaaacttt aacgttaaaa 1320 cctgaaggct ttgtggtaaa agcaaaatcg aaaaaaaattc cgcttggcgg tattccttca 1380 cctagcactg aacagtctgc taaaaaagta cgcaaaaagg cagaaaacgc tcataatacg 1440 ccgctgcttg tgctatacgg ttcaaatatg ggaacagctg aaggaacggc gcgtgattta 1500 gcagatattg caatgagcaa aggatttgca ccgcaggtcg caacgcttga ttcacacgcc 1560 ggaaatcttc cgcgcgaagg agctgtatta attgtaacgg cgtcttataa cggtcatccg 1620 cctgataacg caaagcaatt tgtcgactgg ttagaccaag cgtctgctga tgaagtaaaa 1680 ggcgttcgct actccgtatt tggatgcggc gataaaaact gggctactac gtatcaaaaa 1740 gtgcctgctt ttatcgatga aacgcttgcc gctaaagggg cagaaaacat cgctgaccgc 1800 ggtgaagcag atgcaagcga cgactttgaa ggcacatatg aagaatggcg tgaacatatg 1860 tggagtgacg tagcagccta ctttaacctc gacattgaaa acagtgaaga taataaatct 1920 actctttcac ttcaatttgt cgacagcgcc gcggatatgc cgcttgcgaa aatgcacggt 1980 gcgttttcaa cgaacgtcgt agcaagcaaa gaacttcaac agccaggcag tgcacgaagc 2040 acgcgacatc ttgaaattga acttccaaaa gaagcttctt atcaagaagg agatcattta 2100 ggtgttattc ctcgcaacta tgaaggaata gtaaaccgtg taacagcaag gttcggccta 2160 gatgcatcac agcaaatccg tctggaagca gaagaagaaa aattagctca tttgccactc 2220 gctaaaacag tatccgtaga agagcttctg caatacgtgg agcttcaaga tcctgttacg 2280 cgcacgcagc ttcgcgcaat ggctgctaaa acggtctgcc cgccgcataa agtagctt gaagccttgc ttgaaaagca agcctacaaa gaacagtgc tggcaaaacg tttaacaatg cttgaactgc ttgaaaata cccggcgtgt gaatgaat tcagcgaatt tatcgccctt ctgccaagca tacgcccgcg ctattactcg atttcttcat cacctcgtgt cgatgaaaaa caagcaagca tcacggtcag cgttgtctca ggagaagcgt ggagcggata tggagaatat aaaggaattg cgtcgaacta tcttgccgag ctgcaagaag gagatacgat tacgtgcttt atttccacac cgcagtcaga atttacgctg ccaaaagacc ctgaaacgcc gcttatcatg gtcggaccgg gaacaggcgt cgcgccgttt agaggctttg tgcaggcgcg caaacagcta aaagaacaag gacagtcact tggagaagca catttatact tcggctgccg ttcacctcat gaagactatc tgtatcaaga agagcttgaa aacgcccaaa gcgaaggcat cattacgctt cataccgctt tttctcgcat gccaaatcag ccgaaaacat acgttcagca cgtaatggaa caagacggca agaaattgat tgaacttctt gatcaaggag cgcacttcta tatttgcgga gacggaagcc aaatggcacc tgccgttgaa gcaacgctta tgaaaagcta tgctgacgtt 3060 caccaagtga gtgaagcaga cgctcgctta tggctgcagc agctagaaga aaaaggccga 3120 tacgcaaaag acgtgtgggc tgggtaa 3147 <210> 4 <211> 29 <212> DNA <213> Artificial Sequence <400> 4 cgggatccgc aattaaagaa atgcctcag 29 <210> 5 <211> 28 <212> DNA <213> Artificial Sequence <400> 5 cggaattctt acccagccca cacgtctt 28 <210> 6 <211> 33 <212> DNA <213> Artificial Sequence <400> 6 attaagaatg taataatttg atagcgaatg ttc 33 <210> 7 <211> 23 <212> DNA <213> Artificial Sequence <400> 7 tgcgggacac gtaacaacaa gtg 23 <210> 8 <211> 25 <212> DNA <213> Artificial Sequence <400> 8 agacgggtta ggtacaagct ggacg 25 <210> 9 <211> 26 <212> DNA <213> Artificial Sequence <400> 9 cctgcaaaat cacgtacaaa tttaag 26

Claims

1. Application of a cytochrome P450 BM3 mutant enzyme in biocatalytic synthesis of p-hydroxybiphenyl from biphenyl, characterized in that: The nucleotide sequence encoding the cytochrome P450 BM3 mutant enzyme is shown in SEQ ID NO: 2 or SEQ ID NO:

3.

2. Use of a nucleic acid molecule encoding a cytochrome P450 BM3 mutant enzyme in biocatalytic synthesis of p-hydroxybiphenyl from biphenyl, characterized in that: The nucleotide sequence of the nucleic acid molecule encoding the cytochrome P450 BM3 mutant enzyme is shown in SEQ ID NO: 2 or SEQ ID NO:

3.

3. Application of cytochrome P450 BM3 mutant enzyme expression vector in biocatalytic synthesis of p-hydroxybiphenyl from biphenyl, characterized in that: The expression vector contains a nucleic acid molecule encoding a cytochrome P450 BM3 mutant enzyme, and the nucleotide sequence of the nucleic acid molecule is shown in SEQ ID NO: 2 or SEQ ID NO:

3.

4. Use of a recombinant bacterium or an engineered cell line containing a cytochrome P450 BM3 mutant enzyme expression vector in biocatalytic synthesis of p-hydroxybiphenyl from biphenyl, characterized in that: The expression vector contains a nucleic acid molecule encoding a cytochrome P450 BM3 mutant enzyme, and the nucleotide sequence of the nucleic acid molecule is shown in SEQ ID NO: 2 or SEQ ID NO:

3.

5. A method for catalyzing biphenyl to synthesize p-hydroxybiphenyl, characterized in that: The method comprises: taking biphenyl as substrate and using cytochrome P450 BM3 mutant enzyme to catalyze the synthesis of product p-hydroxybiphenyl, wherein the nucleotide sequence encoding the cytochrome P450 BM3 mutant enzyme is shown in SEQ ID NO: 2 or SEQ ID NO:

3.

6. The method according to claim 5, characterized in that The method specifically comprises: adding cytochrome P450 BM3 mutant enzyme into a buffered reaction solution, then adding substrate biphenyl and NADPH to mix and perform biocatalytic reaction, and obtaining p-hydroxybiphenyl through separation.